Over 1,000 Patients Enrolled in Landmark SELUTION DeNovo Study

This will complement the substantial experience that the company has gained with the SELUTION DeNovo trial in Europe.MedAlliances unique DEB technology involves MicroReservoirs which contain a mixture of biodegradable polymer intermixed with the anti-restenotic drug sirolimus applied as a coating on the surface of an angioplasty balloon.

Related Keywords

China ,Japan ,United States ,Paris ,France General ,France ,Switzerland ,Nyon ,Switzerland General ,Richard Kenyon ,Medalliance ,Christian Spaulding ,Georges Pompidou ,Cardiology Department ,Cell Adherent Technology ,European Hospital Georges Pompidou ,Paris Cit ,Medalliance Chairman ,Middle East ,Jeffreyb Jump ,Co Principal Investigator ,Sia ,Medalliance Medalliance ,E Mark Approval ,Lyon ,Americas ,Aris Cit 233 University ,Cordis ,Elution Denovo ,